Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on February 17, 2003

Hypertension. 2003
Published online before print February 17, 2003, doi: 10.1161/01.HYP.0000056601.29613.DD
A more recent version of this article appeared on March 1, 2003
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
41/3/499    most recent
01.HYP.0000056601.29613.DDv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Badenhorst, D.
Right arrow Articles by Norton, G. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Badenhorst, D.
Right arrow Articles by Norton, G. R.

Submitted on August 6, 2002
Revised on August 26, 2002

{beta}-Adrenergic Activation Initiates Chamber Dilatation in Concentric Hypertrophy

Danelle Badenhorst; Demetri Veliotes; Muzi Maseko; Oupa J. Tsotetsi; Richard Brooksbank; Alvin Naidoo; Angela J. Woodiwiss*; and Gavin R. Norton

From the Cardiovascular Pathophysiology Research Unit, School of Physiology, University of the Witwatersrand Medical School (D.B., D.V., M.M., O.J.T., R.B., A.N., A.J.W., G.R.N.), Johannesburg, South Africa; and the Department of Physiology, Medical University of South Africa (O.J.T.), Johannesburg, South Africa.

* To whom correspondence should be addressed. E-mail: woodiwissaj{at}physiology.wits.ac.za.

Abstract--It is uncertain whether chronic {beta}-adrenoreceptor ({beta}-AR)-activation in hypertension could initiate the progression from compensated left ventricular (LV) hypertrophy to pump dysfunction. It is also uncertain if this effect is through adverse LV remodeling (chamber dilatation with wall thinning and pump dysfunction) or intrinsic myocardial contractile dysfunction. We evaluated the effect of 5 months of isoprenaline (0.02 mg · kg-1 · d-1) on hemodynamics, LV wall thickness, cavity size, and interstitial characteristics in spontaneously hypertensive rats (SHR) with compensated LV hypertrophy. In the absence of myocyte necrosis, changes in volume preload, pressure afterload, and heart rate or decreases in baseline systolic myocardial elastance (load independent measure of intrinsic myocardial contractility), ISO produced a right shift in LV diastolic pressure-volume (P-V) relations (chamber dilatation), a decrease in LV wall thickness despite a further increase in LV weight in SHR, LV pump dysfunction (right shift in LV systolic P-V relations), and deleterious interstitial remodeling (increments in total and noncrosslinked myocardial collagen concentrations). The isoprenaline-induced LV geometric, chamber performance, and interstitial changes were similar to alterations noted during decompensation in older SHR. In summary, in the absence of tissue necrosis and baseline intrinsic myocardial contractile dysfunction, chronic {beta}-AR activation induces interstitial and chamber remodeling and, hence, pump dysfunction. These data suggest that chronic sympathetic activation initiates the progression from compensated concentric LV hypertrophy in hypertension to cardiac dysfunction primarily through deleterious cardiac remodeling rather than intrinsic myocardial contractile dysfunction.


Key words: {beta}-adrenergic • hypertrophy • remodeling • cardiac dysfunction • collagen




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. Berni, M. Savi, L. Bocchi, F. Delucchi, E. Musso, C. Chaponnier, G. Gabbiani, S. Clement, and D. Stilli
Modulation of actin isoform expression before the transition from experimental compensated pressure-overload cardiac hypertrophy to decompensation
Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1625 - H1632.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
O. E. Osadchii, G. R. Norton, R. McKechnie, D. Deftereos, and A. J. Woodiwiss
Cardiac dilatation and pump dysfunction without intrinsic myocardial systolic failure following chronic beta-adrenoreceptor activation
Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1898 - H1905.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. Baek and M. Weiss
Down-Regulation of Na+ Pump {alpha}2 Isoform in Isoprenaline-Induced Cardiac Hypertrophy in Rat: Evidence for Increased Receptor Binding Affinity but Reduced Inotropic Potency of Digoxin
J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 731 - 739.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
D. G.A. Veliotes, A. J. Woodiwiss, D. A.J. Deftereos, D. Gray, O. Osadchii, and G. R. Norton
Aldosterone Receptor Blockade Prevents the Transition to Cardiac Pump Dysfunction Induced by {beta}-Adrenoreceptor Activation
Hypertension, May 1, 2005; 45(5): 914 - 920.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. Gibbs, D. G. A. Veliotes, C. Anamourlis, D. Badenhorst, O. Osadchii, G. R. Norton, and A. J. Woodiwiss
Chronic {beta}-adrenoreceptor activation increases cardiac cavity size through chamber remodeling and not via modifications in myocardial material properties
Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2762 - H2767.
[Abstract] [Full Text] [PDF]